Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
OncoCyte Corporation (OCX) had Return on Equity of -121.43% for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$1.50M |
|
$-28.72M |
|
$1.09M |
|
$0.41M |
|
$26.64M |
|
$-25.14M |
|
$0.28M |
|
$-24.86M |
|
$-24.86M |
|
$-24.86M |
|
$-24.86M |
|
$-27.78M |
|
$-24.86M |
|
$-25.14M |
|
$-23.46M |
|
7.65M |
|
7.65M |
|
$-3.75 |
|
$-3.75 |
|
| Balance Sheet Financials | |
$10.70M |
|
$3.80M |
|
$64.19M |
|
$74.89M |
|
$7.19M |
|
-- |
|
$47.23M |
|
$54.42M |
|
$20.47M |
|
$-36.13M |
|
$20.47M |
|
8.26M |
|
| Cash Flow Statement Financials | |
$-23.32M |
|
$-0.93M |
|
$12.19M |
|
$23.20M |
|
$11.13M |
|
$-12.07M |
|
$2.76M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.49 |
|
-- |
|
-- |
|
-- |
|
-- |
|
27.48% |
|
-1672.39% |
|
-1672.39% |
|
-1560.61% |
|
-1653.69% |
|
-1911.05% |
|
$-23.25M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
3.11 |
|
117.54 |
|
|
Return on Equity |
-121.43% |
68.80% |
|
-33.19% |
|
-121.43% |
|
$2.48 |
|
$-3.04 |
|
$-3.05 |
|